All In Biotech

Drug Trial Radar · NCT07700667

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 13, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into two parts: the safety run-in phase and the cohort expansion phase.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • SKB500Drug

    SKB500 will be administered as an intravenous infusion(IV), every 3 weeks on Day 1 of each 21-day cycle.

  • TislelizumabDrug

    Tislelizumab will be administered as an intravenous infusion(IV) every 3 weeks on Day 1 of each 21-day cycle .

  • CisplatinDrug

    Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • 5 - FUDrug

    5-FU will be administered as an intravenous infusion(IV) every 3 weeks on Day 1-5 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 24 months
  2. Incidence and severity of adverse events (AEs) and serious adverse event(SAEs)Time frame: up to 24 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Chengdu Fifth People's Hospital

    Chengdu, China · Recruiting

  • Sichuan Cancer Hospital & Institute

    Chengdu, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Chongqing University Three Gorges Hospital

    Chongqing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, China · Recruiting

  • Cancer Hospital of Shantou University Medical College

    Shantou, China · Recruiting

  • Cancer Hospital of Dalian University of Technology

    Shenyang, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China · Recruiting

  • Shiyan Renmin Hospital

    Shiyan, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.